On Friday, American Capital Ltd. (NASDAQ:ACAS)’s shares declined -0.40% to $12.52.
American Capital, Ltd. (ACAS) declared that it will report third quarter 2015 earnings after market close on November 4, 2015. Members of the Company’s senior administration team will talk about the quarter on a conference call on November 5, 2015 at 11:00 am ET.
The Company also declared that in conjunction with its reporting of third quarter 2015 earnings, it plans to release forecasts of certain financial information and related assumptions for itself and for American Capital Income, Ltd., the projected new business development company it has formerly declared that it plans to spin-off to its shareholders through a special dividend. The Company anticipates that the forecasted information will cover a three-year period.
American Capital, Ltd. is a private equity and venture capital firm specializing in administration and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s shares gained 6.52% to $9.80.
Intrexon Corporation (XON), a leader in synthetic biology, declared recently it has formed a new Exclusive Channel Partnership(ECC) with ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, for the treatment and prevention of graft-as compared to-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT) which significantly impairs the quality of life and survival of many recipients. The partnershipwill focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2 (IL-2), a cytokine critical for modulation of the immune system.
Through the ECC, the companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells (Tregs) conditionally expressing IL-2 utilizing Intrexon’s proprietary gene control approaches such as its RheoSwitch(R) platform. The second is deployment of orally-delivered microbe-based ActoBiotics(R) therapeutics expressing IL-2 to modulate immune function.
Allogeneic HSCT is used for the treatment of various diseases counting hematological malignancies, immunological deficiencies in addition to non-malignant conditions. About 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient’s (host) cells.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnershipwith Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
At the end of Friday’s trade, Chambers Street Properties (NYSE:CSG)‘s shares surged 0.46% to $6.50.
Chambers Street Properties (CSG), a real estate investment trust focused on acquiring, owning and operating net leased industrial and office properties, recently declared that the Company’s 2015 Annual Meeting of Shareholders (the “2015 Annual Meeting”) has been set for Tuesday, December 15, 2015. The record date for shareholders entitled to notice of and to vote at the 2015 Annual Meeting is October 8, 2015.
Chambers Street Properties is a equity real estate investment trust. The firm invests in the real estate markets of United States, United Kingdom, and Germany. It focuses on acquiring, owning and operating the properties.
Nuance Communications Inc. (NASDAQ:NUAN), ended its Friday’s trading session with 1.54% gain, and closed at $16.51.
Nuance Communications, Inc. (NUAN), declared an extension to the planned partnership with Samsung Electronics to provide Nuance document imaging solutions. Specifically the expansion comprises rights for Samsung to sell and distribute Nuance AutoStore, Equitrac Office/Express and SafeCom. In addition, Nuance will provide service and support to qualifying customers. Recently Nuance powers the voice experiences across a variety of Samsung devices and consumer electronics, counting Samsung’s Smart TV and the S-Voice virtual assistant shipping across a range of Samsung’s Galaxy smartphones, tablets and smart watches.
Nuance solutions, accessible right away to Samsung’s dealer network, comprise:
AutoStore
AutoStore is best suited for business processes capture workflows where participants submit documents and data into a predefined workflow. AutoStore provides a unique experience designed with a responsive and intuitive interface for speed in capturing critical document information with as little interaction as possible using real-time connections to business systems for rapid and error free processing.
Equitrac Office/Express
Equitrac® Office gives businesses the flexibility to let users print what they need and when they need it, while reducing the costs and complexities of deploying a print infrastructure. It is the most intelligent way to print – reducing costs, making printing secure and increasing user satisfaction. With Hybrid Print Control™, Equitrac Office delivers organizational versatility and control, and reduces IT complexities by removing dependencies on print servers, print drivers and complex print fleets—all while managing every printed page in an organization. As user requirements for printing change and IT infrastructure evolves, Equitrac Office lets you easily adapt to these changes with a unique choice of how to deploy printing – using print servers, direct IP printing or a hybrid model that comprises both. This allows you to tailor your print environment according to the specific needs of your users and business.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
